|
Jinxin Fertility Group Limited (1951.HK) Valoración de DCF
CN | Healthcare | Medical - Care Facilities | HKSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Jinxin Fertility Group Limited (1951.HK) Bundle
¡Simplifique la valoración de Jinxin Fertility Group Limited (1951HK) con esta calculadora DCF personalizable! Con un verdadero grupo de fertilidad Jinxin Limited (1951HK) y entradas de pronóstico ajustables, puede probar escenarios y descubrir el valor razonable de Jinxin Fertility Group Limited (1951HK) en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,760.7 | 1,523.2 | 1,964.0 | 2,525.5 | 2,978.8 | 3,440.4 | 3,973.5 | 4,589.3 | 5,300.5 | 6,121.9 |
| Revenue Growth, % | 0 | -13.49 | 28.94 | 28.59 | 17.95 | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 |
| EBITDA | 650.8 | 354.5 | 527.7 | 508.6 | 728.5 | 906.2 | 1,046.6 | 1,208.8 | 1,396.1 | 1,612.5 |
| EBITDA, % | 36.96 | 23.27 | 26.87 | 20.14 | 24.45 | 26.34 | 26.34 | 26.34 | 26.34 | 26.34 |
| Depreciation | 120.2 | 139.2 | 180.7 | 277.7 | 215.3 | 298.5 | 344.8 | 398.2 | 459.9 | 531.2 |
| Depreciation, % | 6.83 | 9.14 | 9.2 | 11 | 7.23 | 8.68 | 8.68 | 8.68 | 8.68 | 8.68 |
| EBIT | 530.6 | 215.3 | 347.0 | 230.9 | 513.2 | 607.7 | 701.8 | 810.6 | 936.2 | 1,081.3 |
| EBIT, % | 30.13 | 14.14 | 17.67 | 9.14 | 17.23 | 17.66 | 17.66 | 17.66 | 17.66 | 17.66 |
| Total Cash | 3,520.5 | 2,637.3 | 2,059.3 | 1,496.6 | 911.0 | 2,682.4 | 3,098.1 | 3,578.2 | 4,132.7 | 4,773.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 46.9 | 98.7 | 338.3 | 283.2 | 304.7 | 329.0 | 379.9 | 438.8 | 506.8 | 585.3 |
| Account Receivables, % | 2.66 | 6.48 | 17.22 | 11.21 | 10.23 | 9.56 | 9.56 | 9.56 | 9.56 | 9.56 |
| Inventories | 27.9 | 27.2 | 50.0 | 66.8 | 66.7 | 74.3 | 85.8 | 99.1 | 114.5 | 132.2 |
| Inventories, % | 1.58 | 1.79 | 2.55 | 2.65 | 2.24 | 2.16 | 2.16 | 2.16 | 2.16 | 2.16 |
| Accounts Payable | 122.7 | 133.2 | 157.4 | 232.5 | 247.0 | 283.7 | 327.7 | 378.4 | 437.1 | 504.8 |
| Accounts Payable, % | 6.97 | 8.75 | 8.01 | 9.21 | 8.29 | 8.25 | 8.25 | 8.25 | 8.25 | 8.25 |
| Capital Expenditure | -296.2 | -284.3 | -85.3 | -1,024.7 | -185.4 | -596.0 | -688.4 | -795.1 | -918.3 | -1,060.6 |
| Capital Expenditure, % | -16.82 | -18.66 | -4.34 | -40.58 | -6.22 | -17.32 | -17.32 | -17.32 | -17.32 | -17.32 |
| Tax Rate, % | 25.75 | 25.75 | 25.75 | 25.75 | 25.75 | 25.75 | 25.75 | 25.75 | 25.75 | 25.75 |
| EBITAT | 396.7 | 155.2 | 257.6 | 181.3 | 381.0 | 454.3 | 524.7 | 606.0 | 699.9 | 808.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 268.7 | -30.6 | 114.8 | -452.3 | 404.1 | 161.5 | 162.5 | 187.7 | 216.8 | 250.4 |
| WACC, % | 8.43 | 8.4 | 8.42 | 8.47 | 8.42 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 758.5 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 260 | |||||||||
| Terminal Value | 5,885 | |||||||||
| Present Terminal Value | 3,927 | |||||||||
| Enterprise Value | 4,686 | |||||||||
| Net Debt | 2,056 | |||||||||
| Equity Value | 2,629 | |||||||||
| Diluted Shares Outstanding, MM | 2,736 | |||||||||
| Equity Value Per Share | 0.96 |
What You Will Receive
- Genuine Jinxin Data: Comprehensive financials – from revenue to EBIT – derived from actual and projected statistics.
- Complete Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Adjustments: Automatic recalculations to assess the effects of changes on Jinxin's fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and in-depth forecasts.
- Efficient and Reliable: Avoid the hassle of constructing models from the ground up while ensuring accuracy and adaptability.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Jinxin Fertility Group Limited (1951HK).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital worksheet with customizable parameters suitable for (1951HK).
- Customizable Forecast Assumptions: Adjust growth projections, capital expenditures, and discount rates as needed for (1951HK).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Jinxin Fertility Group Limited (1951HK).
- Visual Dashboard and Charts: Graphical representations summarize essential valuation metrics for straightforward analysis relating to (1951HK).
How It Functions
- Download the Template: Gain immediate access to the Excel-based Jinxin Fertility Group DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically calculates the intrinsic value of Jinxin Fertility Group (1951HK).
- Test Scenarios: Experiment with different assumptions to assess potential fluctuations in valuation.
- Analyze and Decide: Leverage the results to inform your investment or financial assessments.
Why Choose This Calculator for Jinxin Fertility Group Limited (1951HK)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Adjustable Inputs: Effortlessly change assumptions to suit your analysis needs.
- Real-Time Calculations: Instantly observe how adjustments impact Jinxin's valuation.
- Pre-Loaded Data: Comes with Jinxin's actual financial metrics for swift evaluation.
- Endorsed by Experts: Popular among investors and analysts for informed decision-making.
Who Can Benefit from This Product?
- Institutional Investors: Construct comprehensive and trustworthy valuation models for investment assessments in Jinxin Fertility Group Limited (1951HK).
- Corporate Finance Departments: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Advisory Consultants: Deliver precise valuation insights to clients focusing on Jinxin Fertility Group Limited (1951HK).
- Students and Instructors: Utilize real-world data to enhance financial modeling practice and education.
- Healthcare Sector Analysts: Gain insights into how companies like Jinxin Fertility Group Limited (1951HK) are valued in the healthcare market.
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Jinxin Fertility Group Limited (1951HK), including metrics such as revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for calculating the Weighted Average Cost of Capital (WACC), featuring parameters including Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models that illustrate intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded annual and quarterly financial statements to facilitate thorough analysis.
- Key Ratios: A collection of profitability, leverage, and efficiency ratios relevant to Jinxin Fertility Group Limited (1951HK).
- Dashboard and Charts: A visual overview of valuation outputs and assumptions designed for easy result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.